Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
January 5th, 2018
Targeted gene editing using CRISPR/Cas9 has greatly facilitated the understanding of the biological functions of genes. Here, we utilize the CRISPR/Cas9 methodology to model calreticulin mutations in cytokine-dependent hematopoietic cells in order to study their oncogenic activity.
Overview
This study utilizes CRISPR/Cas9 gene editing to model calreticulin mutations in cytokine-dependent hematopoietic cells. The aim is to investigate the oncogenic activity of these mutations, providing insights into their biological functions.
Key Study Components
Area of Science
- Gene editing
- Oncology
- Hematology
Background
- CRISPR/Cas9 is a powerful tool for targeted gene editing.
- Understanding driver mutations is crucial in hematological malignancies.
- Calreticulin mutations are linked to various cancers.
- This study focuses on their physiological expression levels.
Purpose of Study
- To model calreticulin mutations using CRISPR/Cas9.
- To study the oncogenic activity of these mutations.
- To explore the biological function of driver mutations in hematopoietic cells.
Methods Used
- CRISPR/Cas9 gene editing methodology.
- Modeling mutations in cytokine-dependent hematopoietic cells.
- Analysis of oncogenic activity.
- Experimental procedures for oligo annealing and phosphorylation.
Main Results
- Successful modeling of calreticulin mutations.
- Insights into the oncogenic potential of these mutations.
- Enhanced understanding of driver mutations in cancer biology.
- Potential implications for hematological malignancies research.
Conclusions
- CRISPR/Cas9 is effective for studying gene functions.
- Calreticulin mutations play a significant role in oncogenesis.
- This research contributes to the understanding of hematological cancers.
Frequently Asked Questions
Executive Industry Relevance
CRISPR/Cas9 gene editing enables precise modeling of oncogenic mutations at physiological levels in hematopoietic cells, directly addressing the challenge of functionally validating cancer driver mutations. This approach enhances predictive confidence in target validation and informs risk-adjusted decisions at early discovery and preclinical inflection points. The methodology supports enterprise R&D by providing a scalable platform for interrogating gene function in disease-relevant systems.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional interrogation of driver mutations in endogenous gene contexts.
- Supports biological de-risking by clarifying the oncogenic potential of specific genetic alterations.
- Facilitates predictive confidence in target selection for hematological malignancies.
Screening & Assay Development
- Prepares validated cell models for downstream transformation and proliferation assays.
- Standardizes quantitative readouts for cytokine-independent growth as a surrogate for oncogenic activity.
- Enables reproducible assessment of gene function across multiple guide RNAs and cell lines.
Translational & Preclinical Research
- Aligns disease-relevant genetic models with translational biomarker strategies in hematology.
- Provides continuity from discovery-stage mutation modeling to preclinical validation of oncogenic mechanisms.
- Supports risk-adjusted advancement of targets based on functional evidence in physiologically relevant systems.
Pipeline & Workflow Integration
This CRISPR/Cas9-based workflow integrates from early discovery through preclinical research, enabling iterative hypothesis testing and mechanistic de-risking.
- Discovery Biology: Supports null hypothesis testing for the oncogenicity of specific CALR mutations in hematopoietic cells.
- Screening: Delivers standardized, quantitative proliferation assays to compare mutant and wild-type cell growth.
- Analytics: Provides sequencing and flow cytometry outputs to confirm on-target editing and functional transformation.
- Translational Research: Bridges genetic modeling with disease-relevant phenotypes for biomarker alignment.
- Enterprise Reuse: Offers a modular platform adaptable to other gene targets and cell systems in oncology research.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation and reduces mechanistic ambiguity for driver mutations.
- Operational Value: Standardizes gene editing and selection protocols for reproducibility and scalability.
- Strategic Value: Informs go/no-go decisions by linking genetic alterations to functional transformation in relevant models.
- Portfolio Impact: Enables risk-adjusted prioritization of targets based on robust functional evidence.
Implementation Considerations
- Requires expertise in CRISPR/Cas9 design, lentiviral delivery, and hematopoietic cell culture.
- Demands access to sequencing, flow cytometry, and cell viability analytics for quantitative assessment.
- Necessitates cross-team standardization of guide RNA selection and assay endpoints.
- Adaptable to other genes and cell lines with appropriate optimization of delivery and selection conditions.
- Must observe biosafety protocols for lentiviral work in BL2+ facilities.
Biopharma FAQs
Chapters in this video
0:05
Title
0:44
Cloning sgRNA Oligos
1:08
Digestion of LentiGuide-puroVector
2:04
Ligation of Annealed Oligos into Digested Backbone
3:02
Generation of Cell Lines Stably Expressing spCas9
5:40
Reporter Assay for Cas9 Activity
6:10
Spinfection of sgRNAs into Cas9 Expressing Cells
6:31
Ba/F3 Cellular Transformation and Positive Selection using m-IL3 Withdrawal
7:23
Results: Use of CRISPR/Cas9 Tool and Ba/F3 Cellular Transformation to Study Oncogenic Potential of Mutated Calreticulin
9:02
Conclusion
